THE US Food and Drug
Administration has this month
approved Fulyzaq (crofelemer) for
the relief of symptoms caused by
diarrhea in HIV/AIDS patients taking
antiretroviral therapy.
The drug is derived from the red
sap of the Croton lechleri plant, and
is the second botanical prescription
drug approved by FDA (after Veregen
(sinecatechins), a treatment for
external genital and perianal warts,
was approved in 2006).
Fulyzaq is intended to be used in
HIV/AIDS patients whose diarrhea is
not caused by an infection from a
virus, bacteria, or parasite.
As such, patients are required to
take Fulyzaq two times a day to
manage watery diarrhea due to the
secretion of electrolytes and water
in the gastrointestinal tract.The above article was sent to subscribers in Pharmacy Daily's issue from 09 Jan 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Jan 13
MEDICATION management platform MedAdvisor Limited (MDR) showed strong financial performance for the quarter concluded on 31 Mar 2024, with operating revenue up 42% to $24.2 million from $17 million for the same period last year.
PHARMACIES in regional areas need a restructure of the 8CPA Community Service Obligation (CSO) to help fund them to support their workforce and deliver services, says the Remote and Isolated Pharmacist Association Australia (RIPAA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.